No­var­tis to re­sume the pro­duc­tion of two ra­di­oli­gand ther­a­pies af­ter re­solv­ing qual­i­ty is­sues

Ear­li­er this year, No­var­tis tout­ed its ra­di­oli­gand as a ma­jor piece to counter com­pe­ti­tion in the can­cer space. How­ev­er, the phys­i­cal pro­duc­tion of its prod­ucts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER